Publications: Dr Ozlem Yildiz
Yildiz O, Schroth J, Tree T, Turner MR, Shaw PJ, Henson SM, Malaspina A
(
2022
)
.
Senescent-like Blood Lymphocytes and Disease Progression in Amyotrophic Lateral Sclerosis
.
Neurology Neuroimmunology & Neuroinflammation
vol.
10
,
(
1
)
Allen-Philbey K, Trane SD, Yildiz O, Adams A, Turner B, Marta M, Mathews J, Altmann D et al.
(
2022
)
.
Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a2.3
-
a2a2
.
Yildiz O, Schroth J, Lombardi V, Pucino V, Bobeva Y, Yip PK, Schmierer K, Mauro C et al.
(
2022
)
.
The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis
.
International Journal of Molecular Sciences
vol.
23
,
(
6
)
Thompson AG, Gray E, Verber N, Bobeva Y, Lombardi V, Shepheard SR, Yildiz O, Feneberg E et al.
(
2022
)
.
Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain
.
Brain Communications
vol.
4
,
(
1
)
Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al.
(
2021
)
.
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
.
Therapeutic Advances in Neurological Disorders
vol.
14
,
Puentes F, Lombardi V, Lu C, Yildiz O, Fratta P, Isaacs A, Bobeva Y, Wuu J et al.
(
2021
)
.
Humoral response to neurofilaments and dipeptide repeats in ALS progression
.
Annals of Clinical and Translational Neurology
vol.
8
,
(
9
)
1831
-
1844
.
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up (2528)
.
Neurology
vol.
96
,
(
15_supplement
)
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
90
-
91
.
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up
.
NEUROLOGY
.
vol.
96
,
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Up to 6 years follow-up of people with MS (n=250) receiving cladribine
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
546
-
547
.
Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al.
(
2020
)
.
Severe skin reactions associated with cladribine in people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
.
vol.
43
,
Reyes S, Suarez S, Allen-Philbey K, Yildiz Ö, Mathews J, Anjorin G, Edwards F, Jain C et al.
(
2020
)
.
Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
41
,
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2020
)
.
Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
522
-
523
.
Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al.
(
2019
)
.
192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis?
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
90
,
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al.
(
2019
)
.
Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients (S26.008)
.
Neurology
vol.
92
,
(
15_supplement
)
Mateo-Casas M, Reyes S, De Trane S, Yildiz O, Turner B, Mathews J, Giovannoni G, O’toole E et al.
(
2019
)
.
Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis (P4.2-022)
.
Neurology
vol.
92
,
(
15_supplement
)
De Trane S, Allen-Philbey K, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2019
)
.
Cladribine at all stages of MS: two-year follow-up in 154 patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
519
-
520
.
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al.
(
2019
)
.
Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients
.
NEUROLOGY
.
vol.
92
,
Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, Lu C-H, Leoni E et al.
(
2018
)
.
Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis
.
Molecular Neurodegeneration
vol.
13
,
(
1
)
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al.
(
2018
)
.
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies
.
Multiple Sclerosis and Related Disorders
vol.
27
,
247
-
253
.
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al.
(
2018
)
.
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
vol.
4
,
(
2
)
2055217318783767
-
2055217318783767
.
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al.
(
2018
)
.
Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine
.
Multiple Sclerosis and Related Disorders
vol.
24
,
20
-
27
.
Mao Z, Alvarez-Gonzalez C, Yildiz O, Allen-Philbey K, Turner B, Gnananpavan S, Marta M, Mathews J et al.
(
2018
)
.
Personalised dosing of cladribine for people with multiple sclerosis (P3.400)
.
Neurology
.
vol.
90
,
Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al.
(
2018
)
.
The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. (P2.346)
.
Neurology
.
vol.
90
,
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al.
(
2018
)
.
Cladribine personalised dosing in people with MS (n>200) - four years experience in clinical care
.
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al.
(
2018
)
.
Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
949
-
949
.
Allen-Philbey K, Yildiz O, Raciborska D, Stennett A, Mathews J, Turner B, Giovannoni G, Schmierer K
(
2018
)
.
Systematic multidimensional clinical point-of-care monitoring of people with multiple sclerosis using 3test
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
569
-
569
.